Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review

Frontiers in Oncology

Penelope Jane Barnes¹  Dejan Vidovic²  Lucy Kathryn Helyer²  Carman Anthony Giacomantonio²  Ashley Drohan³ 

[1] Department of Pathology, Dalhousie University, Halifax, NS, Canada;Department of Surgery, Dalhousie University, Halifax, NS, Canada;Department of Surgery, University of Toronto, Toronto, ON, Canada;

关键词: cutaneous breast cancer;    intralesional;    interleukin-2 (IL-2);    IL2;    imiquimod;    intralesional immunotherapy;   

DOI  :  10.3389/fonc.2022.877014

来源: DOAJ

【 摘 要 】

Breast cancer is the most common non-cutaneous cancer affecting women worldwide and is a major cause of cancer-related morbidity and mortality in females. While many women are diagnosed with early-stage disease, a subset of women may present with isolated cutaneous metastases or recurrent locoregional cutaneous metastatic disease. There is a paucity of evidence for effective treatments for cutaneous breast cancer metastases. Herein, we present a case of hormone receptor negative, HER2 positive cutaneous breast cancer metastasis treated with intralesional IL-2 and topical imiquimod, which was well tolerated with only minor low grade side effects. We also present a brief literature review of immunotherapy for cutaneous breast cancer metastasis to frame the discussion around using minimally invasive local therapies for this disease. Together, this limited data suggests that intralesional IL-2 and imiquimod may be considered as a safe option when treating a patient with cutaneous breast cancer metastases.

【 授权许可】

Unknown